Gland Pharma share news, announcements and annual reports
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Gland Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2020 · Issue price ₹1,500
Last close ₹3,095.90up ₹21.40 (0.70%)BSE ₹3,097.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,074.50.
30 Oct: open ₹3,070.00, high ₹3,114.20, low ₹3,051.00
52-week range of traded prices to 30 Oct 2026
₹1,573.60Low, 16 Mar 2026₹3,171.00High, 7 Oct 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹51,086 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.26
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.65%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,00,30260.6% delivered
Gland Pharma results
24 filed, newest first.
Aug 2026
10 Aug · Results
May 2026
15 May · Results
Jan 2026
28 Jan · Results
Nov 2025
3 Nov · Results
Aug 2025
5 Aug · Results
May 2025
20 May · Results
Feb 2025
3 Feb · Results
Nov 2024
4 Nov · Results
Aug 2024
6 Aug · Results
May 2024
22 May · Results
Feb 2024
14 Feb · Results
Nov 2023
6 Nov · Results
Aug 2023
7 Aug · Results
May 2023
18 May · Results
Jan 2023
23 Jan · Results
Oct 2022
Jul 2022
May 2022
19 May · Results
Jan 2022
21 Jan · Results
Oct 2021
22 Oct · Results
Jul 2021
21 Jul · Results
May 2021
17 May · Results
Jan 2021
22 Jan · Results